(Press-News.org) Crawley, UK-- New data, published today in Menopause International, suggests that post-menopausal women in Britain are experiencing less sex, and less satisfying sex compared to their European and North American counterparts1, because they are considerably less likely to access appropriate treatment for a common, taboo condition called vaginal atrophy1.
The first-of-its-kind study, called the CLarifying vaginal atrophy's impact On SEx and Relationships (CLOSER) study, showed that British post-menopausal women with vaginal atrophy are more likely to experience less sex1, and less satisfying sex, compared to other women in Europe and North America (67% and 61% vs 58% and 49% overall, respectively)1. Fear of painful sex was one of the main reasons women avoided intimacy (63%)1, with almost one third of women (30%) and male partners (29%) saying that vaginal discomfort had caused a "big problem" for their sex lives1.
Despite over one and a half million women across the UK potentially experiencing this problem2,4, British women in CLOSER were 50% less likely (21% versus 41% overall) to receive local oestrogen treatment, compared to women from other countries1.
"Given the obvious impact of vaginal atrophy on women in the UK, and their partners, it is very sad to learn that we are lagging behind other Western countries in terms of ensuring appropriate access to treatment," commented Dr Heather Currie, co-author of the study and Associate Specialist Gynaecologist at the Dumfries and Galloway Royal Infirmary, founder of menopausematters.co.uk and Honorary Secretary of the British Menopause Society. "It is our hope that the CLOSER study will encourage our fellow medical professionals, and women themselves, to routinely raise the topic of post-menopausal vaginal health, thereby facilitating appropriate diagnosis and treatment."
Vaginal atrophy is a chronic condition caused by a drop in oestrogen levels, with symptoms including vaginal dryness, itching and painful intercourse5. The condition can have a significant emotional impact, as well as on quality of life, and can lead to serious long-term urogenital problems if left untreated (e.g. incontinence)6.
Local oestrogen, the preferred treatment for vaginal atrophy according to The British Menopause Society7, is applied directly to the vagina while, in systemic hormone therapy, the hormones travel around the entire body7. As vaginal atrophy is a chronic condition, treatment needs to be continued to maintain the benefits7.
"More than two-thirds (68%) of British women in CLOSER used lubricants and moisturisers to treat their vaginal symptoms, but these are not as effective as oestrogen therapy as they do not treat the underlying cause," explained Dr Nick Panay, co-author and Consultant Gynaecologist, Queen Charlotte's & Chelsea and Chelsea & Westminster Hospitals, London, and Immediate Past Chair of the British Menopause Society. "Local oestrogen offers women a well-tolerated and effective solution to vaginal atrophy which, as the CLOSER study illustrates, can significantly disrupt many relationships."
British women who had tried local oestrogen treatment for vaginal atrophy reported beneficial effects such as less painful sex (58%)8, more satisfying sex for their partner (42%)8 and themselves (40%)8, feeling closer and less isolated from their partner (33%)8, having sex more often (27%)8, and saying that they now look forward to having sex (26%)8.
###
A new study in Menopause International reveals how the sex lives of post-menopausal women in Britain are under threat from a common and simple-to-treat symptom of the menopause
The CLOSER study showed how British women with vaginal atrophy were more likely to say they had less sex and found it less satisfying compared to their European and North American counterparts1
British women were 50% less likely to receive appropriate therapy for vaginal atrophy1, with just one in five women (21%) with the condition accessing local oestrogen treatment1
Vaginal symptoms will affect almost half (45%) of all women when they are post-menopausal2, but only a quarter will seek medical advice3
Study authors call for increased awareness and routine discussion1
Media enquiries contact:
Elisa Agate
Edelman
0203 047 2117
Elisa.Agate@edelman.com
Julian Butler
Novo Nordisk FemCare AG
+41 43 222 4331
jbut@novonordisk.com
NOTES TO EDITORS
About the CLOSER research
The CLOSER research was an online survey conducted by StrategyOne (partnering with Ipsos MORI) between 13 December 2011 and 7 February 2012. The survey was completed by 4,100 post-menopausal women, aged between 55-65 who had ceased menstruating for at least 12 months and have experienced vaginal atrophy, and 4,100 male partners of post-menopausal women aged 55-65 who have ceased menstruating for at least 12 months and have experienced vaginal atrophy. The participants were located across nine countries: US, UK, Canada, Denmark, Sweden, Finland, Norway, Italy and France.
The objectives of this research were to better understand the impact that vaginal atrophy has on intimacy and relationships, both physically and emotionally, and to find out how to encourage positive conversations among men and women about this topic. The research also looked at the positive impact that local oestrogen treatment can have on the sufferer's relationship. The global results were first presented at the European Menopause and Andropause Society (EMAS) in March 2012 and the UK data was first presented at the British Menopause Society (BMS) Annual Conference in July 2012.
About vaginal atrophy
Vaginal atrophy, a chronic condition, is the thinning and inflammation of the vaginal wall which occurs when there is a reduction in levels of oestrogens5. Oestrogen, produced by the ovaries, is responsible for maintaining the structure and function of the vaginal wall, elasticity of the tissues around the vagina and production of vaginal fluid. If left untreated, vaginal atrophy can have long-term urogenital effects, including incontinence6.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.co.uk
References
1. Domoney C, Currie H, Panay N, Maamari R, Nappi RE. The CLOSER survey: impact of postmenopausal vaginal discomfort on women and male partners in the UK. Menopause International. June 2013; 19(2):69-76.
2. Nappi RE, Kokot-Kierepa M. Vaginal health: Insights, Views and Attitudes (VIVA) – results from an international survey. Climacteric. February 2012;15:36-44.
3. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722-7.
4. Office for National Statistics. Table 1 2011 Census: Usual resident population by five-year age group and sex, United Kingdom and constituent countries. Last accessed: May 2013.
5. Simon J, et al. Effective Treatment of Vaginal Atrophy With an ultra-Low-Dose Estradiol Vaginal Tablet. Obstetrics & Gynecology. 2008; 112(5):1053-1060.
6. Hextall A. Oestrogens and lower urinary tract function. Maturitas. 2000;36:83-92
7.Panay N, Hamoda H, Arya R and Savvas M on behalf of The British Menopause Society. The 2013 British Menopause Society & Women's Health Concern recommendations on hormone replacement therapy. Menopause International. Published online before print May 2013;Accessble at: http://min.sagepub.com/content/early/2013/05/23/1754045313489645; doi: 10.1177/1754045313489645.
8. Domoney C, et al. Vaginal Health: When intimacy matters! British Menopause Society (BMS) Annual Congress, 2012.
British women 50 percent less likley to recieve treatment for common menopausal symptoms
2013-06-19
ELSE PRESS RELEASES FROM THIS DATE:
No danger of cancer through gene therapy virus
2013-06-19
In fall 2012, the European Medicines Agency (EMA) approved the modified adeno-associated virus AAV-LPL S447X as the first ever gene therapy for clinical use in the Western world. uniQure, a Dutch biotech company, had developed AAV-LPL S447X for the treatment of a rare inherited metabolic disease called lipoprotein lipase deficiency (LPLD) which affects approximately one or two out of one million people. The disease causes severe, life-threatening inflammations of the pancreas. Afflicted individuals carry a defect in the gene coding for the lipoprotein lipase enzyme which ...
Outlook is grim for mammals and birds as human population grows
2013-06-19
COLUMBUS, Ohio – The ongoing global growth in the human population will inevitably crowd out mammals and birds and has the potential to threaten hundreds of species with extinction within 40 years, new research shows.
Scientists at The Ohio State University have determined that the average growing nation should expect at least 3.3 percent more threatened species in the next decade and an increase of 10.8 percent species threatened with extinction by 2050.
The United States ranks sixth in the world in the number of new species expected to be threatened by 2050, the research ...
University of Tennessee professor finds prehistoric rock art connected; maps cosmological belief
2013-06-19
It is likely some of the most widespread and oldest art in the United States. Pieces of rock art dot the Appalachian Mountains, and research by University of Tennessee, Knoxville, anthropology professor Jan Simek finds each engraving or drawing is strategically placed to reveal a cosmological puzzle.
Recently, the discoveries of prehistoric rock art have become more common. With these discoveries comes a single giant one—all these drawing and engravings map the prehistoric peoples' cosmological world.
The research led by Simek, president emeritus of the UT system and ...
New data on islet autoantibodies in young children defines early type 1 diabetes development
2013-06-19
New York, NY, June 19, 2013 – A decade-long JDRF-funded study led by the Institute of Diabetes Research in Helmholtz Zentrum München, Germany, is providing a deeper understanding of the link between autoantibodies and the risk of developing type 1 diabetes (T1D), highlighting the importance of pre-diabetes research into possible preventions for the disease. The study, "Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children," was published today in The Journal of the American Medical Association.
Researchers in Colorado (DAISY study), ...
Breakthrough research of essential molecule reveals important targets in diabetes and obesity
2013-06-19
DETROIT – Insulin is the most potent physiological anabolic agent for tissue-building and energy storage, promoting the storage and synthesis of lipids, protein and carbohydrates, and inhibiting their breakdown and release into the circulatory system. It also plays a major role in stimulating glucose entry into muscle tissue, where the glucose is metabolized and removed from the blood following meals. But gaps exist in understanding the precise molecular mechanisms by which insulin regulates glucose uptake in fat and muscle cells.
A research team led by Assia Shisheva, ...
Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers
2013-06-19
Researchers at Moffitt Cancer Center and colleagues at Louisiana State University have developed a method for identifying aggressive prostate cancers that require immediate therapy. It relies on understanding the genetic interaction between single nucleotide polymorphisms (SNPs). The goal is to better predict a prostate cancer's aggressiveness to avoid unnecessary radical treatment.
Their study was published in the online journal PLOS ONE in April.
According to the authors, prostate cancer accounts for 20 percent of all cancers and 9 percent of cancer deaths. It is ...
An environmentally friendly battery made from wood
2013-06-19
Taking inspiration from trees, scientists have developed a battery made from a sliver of wood coated with tin that shows promise for becoming a tiny, long-lasting, efficient and environmentally friendly energy source. Their report on the device — 1,000 times thinner than a sheet of paper — appears in the journal Nano Letters.
Liangbing Hu, Teng Li and colleagues point out that today's batteries often use stiff, non-flexible substrates, which are too rigid to release the stress that occurs as ions flow through the battery. They knew that wood fibers from trees are supple ...
New canary seed is ideal for gluten-free diets in celiac disease
2013-06-19
A new variety of canary seeds bred specifically for human consumption qualifies as a gluten-free cereal that would be ideal for people with celiac disease (CD), scientists have confirmed in a study published in ACS' Journal of Agricultural and Food Chemistry.
Joyce Irene Boye and colleagues point out that at least 3 million people in the United States alone have CD. They develop gastrointestinal and other symptoms from eating wheat, barley, rye and other grains that contain gluten-related proteins. Boye's team sought to expand dietary options for CD — which now include ...
Pearly perfection
2013-06-19
The mystery of how pearls form into the most perfectly spherical large objects in nature may have an unlikely explanation, scientists are proposing in a new study. It appears in ACS' journal Langmuir, named for 1932 Nobel Laureate Irving Langmuir.
Julyan Cartwright, Antonio G. Checa and Marthe Rousseau point out that the most flawless and highly prized pearls have perhaps the most perfectly spherical, or ball-like, shape among all the objects in nature that are visible without a microscope. Pearls develop as nacre (mother of pearl) and other liquids accumulate around ...
Are we pushing animals over the edge?
2013-06-19
Species of mammals and birds are threatened with extinction as a result of rising human population density, according to Jeffrey McKee and colleagues from The Ohio State University in the US. Their work is also the first to show that the exponential growth of the human population will continue to pose a threat to other species. In other words, there does not appear to be a threshold above which population growth would cease to have an incremental negative effect. The study is published online in Springer's journal, Human Ecology.
It has long been suspected that the number ...